GS-441524
Remdesivir active metabolite / Parent nucleoside and active metabolite of the SARS-CoV2 drug remdesivir. Displayed broad spectrum antiviral activity against HCV, YFV, DENV-2, influenza A, parainfluenza 3, and SARS-CoV.1 It has been suggested that GS-441524 is superior as an anti-SARS-CoV2 drug due to simplicity of preparation compared to remdesivir, lack of on-target liver toxicity, and the fact that remdesivir is prematurely hydrolyzed to GS-441524 in human serum.2 Additionally, the enzymes that hydrolyze remdesivir to active metabolite GS-441524 are hardly expressed in lungs.
Biochemicals & reagents
1191237-69-0
Cho et al. (2012) Synthesis and antiviral activity of a series of 1’-substituted 4-aza-7,9-dideazaadenosine C-nucleosides; Med. Chem. Lett. 22 2705 Yan and Muller (2020) Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment; ACS Med. Chem. Lett. 11 1361
-20°C
TARGET: RNA -- DISEASE AREA: Infectious disease